Pacira Pharmaceuticals Inc (PCRX)

47.00
0.05 0.11
NASDAQ : Health Care
Prev Close 46.95
Open 46.95
Day Low/High 46.35 / 47.65
52 Wk Low/High 31.08 / 80.25
Volume 30.30K
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 39.93M
Market Cap 1.92B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Pacira Pharmaceuticals Tops 4Q Earnings Expectations

Pacira Pharmaceuticals Tops 4Q Earnings Expectations

Pacira (PCRX) reported mixed fourth quarter results.

Short Interest Jumps 15.6% For PCRX

Short Interest Jumps 15.6% For PCRX

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 836,945 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 6,219,273, an increase of 15.55% since 01/13/2017.

Biotech Premarket Movers: Pacira, Clearside Biomedical and Organovo

Biotech Premarket Movers: Pacira, Clearside Biomedical and Organovo

Pacira Pharmaceuticals, Clearside Biomedical and Organovo Holdings are among the premarket biotech movers on Wednesday.

DePuy Synthes Announces Exclusive Co-Promotional Agreement With Pacira Pharmaceuticals, Inc.

DePuy Synthes Announces Exclusive Co-Promotional Agreement With Pacira Pharmaceuticals, Inc.

EXPAREL® Provides Orthopaedic Patients Long-Lasting, Non-Opioid Postsurgical Pain Control at the Surgical Site

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Pacira Pharmaceuticals Reports Preliminary 2016 Revenues Of $276.4 Million

Pacira Pharmaceuticals Reports Preliminary 2016 Revenues Of $276.4 Million

EXPAREL net product sales driven by soft tissue and orthopedic procedures

Choppiness Usually Ends With Some Sort of Decline

Typically, the best way to get sentiment to turn is to take the indexes down.

Interesting PCRX Put And Call Options For August 2017

Interesting PCRX Put And Call Options For August 2017

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2017 expiration.

Pacira Pharmaceuticals And GeneAlign Announce Partnership To Develop Low-Opioid Pain Management Protocols For Postsurgical Patients At High Risk Of Addiction

Pacira Pharmaceuticals And GeneAlign Announce Partnership To Develop Low-Opioid Pain Management Protocols For Postsurgical Patients At High Risk Of Addiction

Collaboration will leverage genetic testing to identify patients predisposed to developing addiction following opioid exposure

Interesting PCRX Put And Call Options For January 2017

Interesting PCRX Put And Call Options For January 2017

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2017 expiration.

American College Of Surgeons Launches Education Program On Opioids And Surgery: Use, Abuse, And Alternatives

American College Of Surgeons Launches Education Program On Opioids And Surgery: Use, Abuse, And Alternatives

Pacira grant will allow for the development and distribution of resources to educate patients and surgeons on opioid use in surgical care

Analysts' Actions -- Quintiles, Royal Caribbean, Western Digital and More

Analysts' Actions -- Quintiles, Royal Caribbean, Western Digital and More

Here are Thursday's top research calls, including an upgrade for Western Digital and downgrades for Quintiles and Royal Caribbean.

First Week of December 16th Options Trading For Pacira Pharmaceuticals (PCRX)

First Week of December 16th Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the December 16th expiration.

Pacira Pharmaceuticals Continues To Build Out Robust Commercial Leadership Team

Pacira Pharmaceuticals Continues To Build Out Robust Commercial Leadership Team

Company Appoints Thomas Sluby as Vice President, Sales and Matthew Lehmann as Vice President, Marketing